<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="184335">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694356</url>
  </required_header>
  <id_info>
    <org_study_id>0646-009</org_study_id>
    <secondary_id>2008_012</secondary_id>
    <nct_id>NCT00694356</nct_id>
  </id_info>
  <brief_title>Study of MK0646 in Patients With Solid Tumors (0646-009)(COMPLETED)</brief_title>
  <official_title>A Phase I Study of MK0646 in Patients With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A clinical study evaluates the safety, tolerability, pharmacokinetics, and immunogenicity of
      MK0646 in patients with relapsed or refractory locally advanced or metastatic solid tumors
      using a once weekly and an every other week dose infusion regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any clinical or laboratory adverse experience.</measure>
    <time_frame>Duration of Treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Duration of Treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0646</intervention_name>
    <description>MK0646 (5 or 10 mg/kg) IV infusion once weekly for 4 consecutive weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically- Or Cytologically- Confirmed Metastatic Or Locally Advanced Solid
             Tumors That Has Failed To Respond To Standard Therapy, Or For Which Adequate Standard
             Therapy Dose Not Exist

          -  Tumors Associated With Igf-1r Expression In The Literature (E.G. Prostate,
             Pancreatic, Colon, Lung And Breast)

          -  Ecog Performance Status 0 or 1

          -  Adequate Organ Function

        Exclusion Criteria:

          -  Patient Who Has Had Chemotherapy, Radiotherapy, Or Biological Therapy Within 4 Weeks
             (6 Weeks For Nitrosoureas Or Mitomycin C) Prior To Registration

          -  Patients Is Concurrently Using Growth Hormone (Gh), Or Growth Hormone Inhibitor

          -  Any Active CNS Metastases And/Or Carcinomatous Meningitis

          -  Any Primary Central Nervous System Tumor - Any Symptomatic Ascites Or Plural Effusion

          -  A History Or Current Evidence Of Any Clinically Significant Disease That Might
             Confound The Results Of The Study, Complicate The Interpretation Of The Study
             Results, Interfere With The Patient'S Participation, Or Pose An Additional Risk To
             The Patient

          -  Pregnant Or Breast-Feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 4, 2015</lastchanged_date>
  <firstreceived_date>May 29, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
